Neuroendocrine Tumors: Clinical Trials

4,550 trials for Neuroendocrine Tumors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2069 completed, 631 terminated, 621 recruiting, 488 unknown. 1897 Phase 2, 1473 Phase 1, 506 Not applicable, 268 Phase 3, 84 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 21897Completed 844, Terminated 332, Recruiting 228, Unknown 179, Active not recruiting 166, Withdrawn 87, Not yet recruiting 49, Suspended 10, Enrolling by invitation 2
Phase 11473Completed 677, Terminated 283, Recruiting 187, Active not recruiting 120, Unknown 114, Withdrawn 57, Not yet recruiting 22, Suspended 11, Enrolling by invitation 2
Not applicable506Completed 245, Recruiting 100, Unknown 64, Terminated 30, Active not recruiting 28, Not yet recruiting 17, Withdrawn 16, Enrolling by invitation 3, Suspended 3
Phase 3268Completed 121, Recruiting 40, Active not recruiting 39, Terminated 34, Unknown 23, Withdrawn 7, Not yet recruiting 4
Early Phase 184Completed 32, Terminated 15, Recruiting 11, Active not recruiting 10, Unknown 7, Withdrawn 5, Not yet recruiting 4
Phase 457Completed 22, Unknown 10, Recruiting 9, Not yet recruiting 6, Terminated 4, Withdrawn 4, Active not recruiting 2

Follow Neuroendocrine Tumors: new trials by email Literature Review of Neuroendocrine Tumors trials Research Report on Neuroendocrine Tumors

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma
Not applicableNot yet recruitingJonsson Comprehensive Cancer Center1002027-09-022026-10-19
Combination Immunotherapy Targeting Melanoma
Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-10-30
Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma
Temozolomide (TMZ) - Cutaneous Melanoma
Phase 2Not yet recruitingAssistance Publique Hopitaux De Marseille282027-06-012026-09-08
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Phase 2RecruitingChildren's Oncology Group512027-05-152026-09-24
Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma
Phase 2Not yet recruitingNorthwestern University562027-05-052026-10-07
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy - Malignant Melanoma With Metastasis, Malignant Melanoma
Phase 2Not yet recruitingRapa Therapeutics LLC652027-03-012026-03-19
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma
Phase 2Not yet recruitingM.D. Anderson Cancer Center202027-02-072026-09-18
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Uveal Melanoma, Metastatic Cutaneous Melanoma
Phase 1Not yet recruitingVastra Gotaland Region62027-01-312026-09-09
Zanzalintinib in Unresectable and Progressive MPGGs
Zanzalintinib - Pheochromocytoma, Paraganglioma
Phase 2Not yet recruitingDana-Farber Cancer Institute142027-01-092026-07-20
Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults
Mirdametinib - LGCMN, Large and Giant Congenital Melanocytic Nevi
Phase 2Not yet recruitingNational Cancer Institute (NCI)152027-01-042026-10-29
Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma
Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma
Phase 1Not yet recruitingVastra Gotaland Region182027-01-012026-09-09
Role of ChatGPT in Vestibular Schwannoma Management
Use of chatGPT for 1 week - Vestibular Schwannoma
Not applicableWithdrawnUniversity of Southern California2027-01-012026-01-13
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
Not applicableNot yet recruitingNatera, Inc.9202027-01-012026-10-27
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma
Phase 1Not yet recruitingAccSalus Biosciences, Inc.402027-01-012026-10-28
Prospective, Multi-Center Observational Registry of Melanoma CP-GEP and Clinical Outcomes
Melanoma (Skin Cancer), Gene Expression Profiling
Not yet recruitingSkylineDx20002027-01-012026-11-13
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
ICI Therapy - Gastrointestinal Neoplasms, Genitourinary Cancer
Early Phase 1Not yet recruitingIndiana University802027-01-012026-11-18
Neoadjuvant RP2 + Nivolumab in Patients With Melanoma
RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection - MelanomaCutaneous Melanoma Resectable, Melanoma
Phase 2Not yet recruitingYana Najjar342026-12-312026-10-07
Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma
Wide Local Excision - Cutaneous Melanoma, Stage II, Cutaneous Melanoma
Not applicableNot yet recruitingUniversity of Nebraska2822026-12-242026-10-09
Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy
Biospecimen Collection, Internet-Based Intervention, Medical Device Usage and Evaluation - Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Phase 1Not yet recruitingCity of Hope Medical Center82026-12-232026-06-05
Everolimus Post-Bland Hepatic Artery Embolization in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis
Everolimus, Bland Hepatic Artery Embolization - Neuroendocrine Tumors, Liver Metastases
Phase 2Not yet recruitingLowell Anthony, MD122026-12-162026-11-18

Showing 20 of 4550. Sign in to see all of them.

Narrower conditions

Melanoma (3205)  ·  Carcinoma, Non-Small-Cell Lung (451)  ·  Neoplasms (399)  ·  Neoplasm Metastasis (353)  ·  Carcinoma, Renal Cell (325)  ·  Breast Neoplasms (319)  ·  Uveal Melanoma (280)  ·  Colorectal Neoplasms (257)  ·  Lung Neoplasms (246)  ·  Skin Neoplasms (221)  ·  Ovarian Neoplasms (209)  ·  Sarcoma (202)  ·  Pancreatic Neoplasms (201)  ·  Squamous Cell Carcinoma of Head and Neck (178)

Broader conditions

Neuroectodermal Tumors (4544)  ·  Neoplasms by Histologic Type (4534)  ·  Neoplasms, Germ Cell and Embryonal (4531)  ·  Neoplasms, Nerve Tissue (4513)  ·  Neoplasms (4151)  ·  Neoplasms by Site (3836)  ·  Nevi and Melanomas (3376)  ·  Skin and Connective Tissue Diseases (3269)  ·  Skin Diseases (3256)  ·  Skin Neoplasms (3008)  ·  Neoplasms, Glandular and Epithelial (1240)  ·  Carcinoma (1068)  ·  Adenocarcinoma (914)  ·  Thoracic Neoplasms (679)

Interventions

pembrolizumab (340)  ·  Nivolumab (315)  ·  Ipilimumab (282)  ·  Cyclophosphamide (151)  ·  aldesleukin (145)  ·  Interleukin-2 (112)  ·  Temozolomide (105)  ·  trametinib (85)  ·  Dacarbazine (83)  ·  dabrafenib (77)  ·  fludarabine (75)  ·  Vemurafenib (71)  ·  Bevacizumab (68)  ·  Everolimus (67)  ·  fludarabine phosphate (65)

Sponsors

National Cancer Institute (NCI) (288)  ·  M.D. Anderson Cancer Center (135)  ·  Bristol-Myers Squibb (90)  ·  Memorial Sloan Kettering Cancer Center (86)  ·  Novartis Pharmaceuticals (70)  ·  H. Lee Moffitt Cancer Center and Research Institute (53)  ·  Hoffmann-La Roche (48)  ·  Mayo Clinic (47)  ·  Pfizer (42)  ·  Merck Sharp & Dohme LLC (39)  ·  Dana-Farber Cancer Institute (37)  ·  GlaxoSmithKline (28)  ·  University Medical Center Groningen (28)  ·  Massachusetts General Hospital (27)  ·  University Health Network, Toronto (27)

Countries

United States (2612)  ·  France (513)  ·  Italy (382)  ·  Spain (361)  ·  Germany (359)  ·  United Kingdom (350)  ·  Australia (331)  ·  Canada (317)  ·  China (291)  ·  Netherlands (246)  ·  Belgium (199)  ·  Switzerland (177)  ·  Poland (148)  ·  Israel (126)  ·  South Korea (125)

Top investigators

Steven A Rosenberg, M.D. (30)  ·  Steven A. Rosenberg, MD, PhD (27)  ·  F. Stephen Hodi, MD (14)  ·  Paul Chapman, MD (10)

Results publications

PMID 36648215, PMID 25667295, PMID 24983357, PMID 39504507, PMID 22555974, PMID 22256804, PMID 25649350, PMID 26446943, PMID 31395089, PMID 31401903, PMID 32746839, PMID 37934000, PMID 23457002, PMID 23861247, PMID 24408395, PMID 24577748, PMID 27864013, PMID 30202085, PMID 30736858, PMID 32305010, PMID 32747469, PMID 33360855, PMID 34225229, PMID 34754076, PMID 36653848, PMID 39462179, PMID 40341199, PMID 40721981, PMID 41811823, PMID 17917842, PMID 19097774, PMID 19574236, PMID 19645909, PMID 20856802, PMID 21600759, PMID 21639810, PMID 22027076, PMID 23054107, PMID 23295794, PMID 23504141, PMID 23676418, PMID 24145345, PMID 24418949, PMID 24695685, PMID 25432172, PMID 25837513, PMID 26247776, PMID 26902923, PMID 28592387, PMID 28662232

NIH funding

2023 (45), 2019 (38), 2016 (30), 2018 (28), 2014 (20), 2015 (18), P30CA015083 (18), U10CA032102 (16), P30CA016672 (15), U10CA180820 (15), 2025 (13), 2009 (12), 2017 (12), P30CA015704 (12), P30CA072720 (12)